Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.50 |
| ▸ | RORA | P35398 | 3/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 13/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 12/20 | 0.47 |
| ▸ | RORB | Q92753 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21886392 | 0.86 | RORC (0.46) | RORCRORANR1H3NR1H2HTR2A | |
| SCHEMBL128187 | 0.83 | RORC (0.44) | RORCRORANR1H3NR1H2HTR2A | |
| SCHEMBL1871995 | 0.83 | NR1H2 (0.46) | RORCRORANR1H3NR1H2 | |
| SCHEMBL10087869 | 0.82 | NR1H2 (0.47) | RORCRORANR1H3NR1H2 | |
| SCHEMBL10686965 | 0.81 | NR1H2 (0.52) | RORCRORANR1H3NR1H2 | |
| SCHEMBL832913 | 0.81 | NR1H3 (0.47) | RORCRORANR1H3NR1H2 | |
| SCHEMBL16105797 | 0.80 | HTR2A (0.46) | HTR2AHTR2CHTR2B | |
| SCHEMBL14339435 | 0.80 | KIF11 (0.47) | HTR2AHTR2CHTR2B | |
| SCHEMBL6377331 | 0.80 | HTR2A (0.46) | HTR2AHTR2CHTR2B | |
| SCHEMBL5358396 | 0.80 | HTR2A (0.46) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | RORC 3771/4885RORA 4413/4885NR1H3 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.